Results 41 to 50 of about 4,821 (183)

Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016Plain-language summary

Kidney Medicine, 2021
Background: Information regarding the use of glucose-lowering medications in patients with chronic kidney disease (CKD) is limited. Study Design: Retrospective cohort study.
Julie Z. Zhao, Eric D. Weinhandl, Angeline M. Carlson, Wendy L. St. Peter   +3 more
doaj   +1 more source

Once-Weekly Exenatide as Adjunct Treatment of Type 1 Diabetes Mellitus in Patients Receiving Continuous Subcutaneous Insulin Infusion Therapy [PDF]

, 2014
Objective The use of once-weekly exenatide in type 2 diabetes mellitus is well supported, but little is known about its effectiveness in type 1 diabetes.
Hui, Adrian C., Lull, Melinda E., Lyons-Patterson, Jane, Traina, Andrea N., Zahorian, Toni M.   +4 more
core   +2 more sources

Structure-based insight into development of selective and non-selective amylin and calcitonin receptor agonists

, 2022
Abstract Targeting amylin (Amy) receptors (AMYRs) can reduce body weight with additional benefits to other anti-obesity treatments such as glucagon-like peptide-1 receptor (GLP-1R) agonists. AMYRs are heterodimers of the calcitonin receptor (CTR) and one of three receptor activity-modifying proteins (RAMPs), yielding AMY1R, AMY2R and AMY3R ...
Jianjun Cao, Matthew Belousoff, Radostin Danev, Madeleine Fletcher, Emma dal Maso, Herman Schreuder, Katrin Lorenz, Andreas Evers, Garima Tiwari, Melissa Besenius, Ziyu Li, Rachel Johnson, Denise Wootten, Patrick M. Sexton   +13 more
openaire   +1 more source

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes [PDF]

, 2011
It is important for patients that treatments for diabetes not increase cardiovascular (CV) risk. The objective of this analysis was to examine retrospectively the CV safety of exenatide BID, a GLP-1 receptor agonist approved for treating hyperglycemia in
Robert Ratner, Jenny Han, Dawn Nicewarner, Irina Yushmanova, Byron J Hoogwerf, Larry Shen   +5 more
core   +1 more source

Novos fármacos para o tratamento da obesidade [PDF]

, 2009
Central obesity have an important impact on the development of risk factors for coronary heart disease, including dislipidemia, glucose intolerance, insulin resistance and hypertension.
Ribeiro Filho, Fernando Flexa, Zanella, Maria Teresa   +1 more
core   +3 more sources

A dual amylin and calcitonin receptor agonist inhibits pain behavior and reduces cartilage pathology in an osteoarthritis rat model [PDF]

Osteoarthritis and Cartilage, 2019
Pain and disability are the main clinical manifestations of osteoarthritis, for which only symptomatic therapies are available. Hence, there is a need for therapies that can simultaneously alter disease progression and provide pain relief. KBP is a dual amylin- and calcitonin-receptor agonist with antiresorptive and chondroprotective properties.
A, Katri, A, Dąbrowska, H, Löfvall, M A, Karsdal, K V, Andreassen, C S, Thudium, K, Henriksen   +6 more
openaire   +2 more sources

Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss

Biomedicine & Pharmacotherapy, 2023
Dual amylin and calcitonin receptor agonists (DACRAs) are known to induce significant weight loss as well as improve glucose tolerance, glucose control, and insulin action in rats. However, to what extent DACRAs affect insulin sensitivity beyond that induced by weight loss and if DACRAs affect glucose turnover including tissue-specific glucose uptake ...
Anna Thorsø, Larsen, Simone A, Melander, Nina, Sonne, Emma, Bredtoft, Mays, Al-Rubai, Morten A, Karsdal, Kim, Henriksen   +6 more
openaire   +2 more sources

New pharmacological perspectives for the leptin receptor in the treatment of obesity [PDF]

, 2014
International audienceAfter its discovery in 1994, leptin became the great hope as an anti-obesity treatment based on its ability to reduce food intake and increase energy expenditure.
Dam, Julie, Jockers, Ralf, Roujeau, Clara   +2 more
core   +5 more sources

Treatment with a dual amylin and calcitonin receptor agonist improves metabolic health in an old, obese, and ovariectomized rat model

Menopause, 2021
Abstract Objectives: Menopause is often characterized by detrimental metabolic changes, such as obesity, insulin resistance, and impaired glucose tolerance, often requiring treatment. KeyBioscience Peptides (KBPs) are Dual Amylin and Calcitonin Receptor Agonists which have shown promising metabolic effects in rats ...
Katri, Anna, Reker, Ditte, Karsdal, Morten A., Bay-Jensen, Anne-Christine, Henriksen, Kim   +4 more
openaire   +3 more sources

Receptor activity modifying protein-directed G protein signaling specificity for the calcitonin gene-related peptide family of receptors [PDF]

, 2016
The calcitonin gene-related peptide (CGRP) family of G protein-coupled receptors (GPCRs) is formed through association of the calcitonin receptor-like receptor (CLR) and one of three receptor activitymodifying proteins (RAMPs).
Weston, Cathryn, Winfield, Ian, Harris, Matthew, Hodgson, Rose, Shah, Archna, Dowell, Simon J, Mobarec, Juan Carlos, Woodlock, David A, Reynolds, Christopher A, Poyner, David R, Watkins, Harriet A, Ladds, Graham   +11 more
core   +4 more sources